Compare on twelve month total value, not the advertised first month. The number that decides which provider is better for a given person is the sum of medication at the dose actually reached, any membership or consultation fee, lab work, shipping, and the cost of the months where nothing changes. Medvi and its main alternatives look very different once that arithmetic is done.
Why the headline price is close to meaningless
Almost every cash-pay program in this market prices the first month below the ongoing rate. That is a legitimate acquisition offer and it is disclosed, but it makes cross-provider comparison on the advertised figure useless. Two programs with identical introductory pricing can differ by several hundred dollars a year once the standard rate applies.
Dose is the second distortion. GLP-1 medication is titrated upward over months, and most cash-pay pricing rises with dose. A program quoting the entry strength is quoting a price the patient will pass through in a few weeks. The honest comparison uses the price at a maintenance dose, which is where the patient will spend most of the year.
The real field, and what each type optimizes for
The alternatives fall into three groups. Branded telehealth platforms such as Hims and Hers, Ro and LifeMD sell access to clinicians and increasingly route patients toward the approved branded drugs where the patient can afford them. Compounded cash-pay programs, the group Medvi sits in, price on medication supply with clinician oversight attached. Behavior-led programs such as Noom and WeightWatchers Clinic price coaching first and medication second.
Separately, the manufacturers themselves now sell direct. Eli Lilly and Novo Nordisk both operate direct-pay channels for their approved products at prices well below list, which matters because those are FDA-approved medications rather than compounded preparations. Any comparison that leaves the manufacturer channels out is incomplete, whatever the compounded price looks like.
Within the cash-pay compounded group the individual programs line up more cleanly than they first appear. A provider such as HealthRX lists its GLP-1 treatment options and membership pricing directly, which makes it straightforward to drop into the same twelve month table as Henry Meds, Ro, or a manufacturer channel like NovoCare. The value work is in filling every row for each of them at the maintenance dose, not in settling on brand reputation before the numbers are in.
| Cost or value component | Why it moves the total | Question to ask before enrolling |
|---|---|---|
| Maintenance dose price | Sets the cost of nine to ten months of the year | What does the highest dose cost per month? |
| Membership or consult fee | Charged whether or not medication ships | Is the fee separate from the medication price? |
| Lab work | Required by some programs, optional at others | Are labs included, extra, or not requested? |
| Shipping and cold chain | Small per order, meaningful over a year | Is shipping bundled into the quoted price? |
| Prepaid commitment | Lowers the rate, raises the exit cost | How are unshipped months treated on exit? |
| Drug status | Approved product versus compounded preparation | Is this an FDA-approved medicine or a compounded one? |
Approved versus compounded is a value question, not just a safety one
Compounded semaglutide and tirzepatide are not FDA-approved. The agency has not evaluated the finished preparation for safety, effectiveness or manufacturing quality, and a pharmacovigilance analysis of adverse event reports involving compounded GLP-1 products found a signal profile worth taking seriously. That does not make compounded medication unlawful, and prescribing it is a recognized clinical practice, but it belongs in the value calculation rather than being treated as an equivalent product at a lower price.
The counterweight is access. Manufacturer direct pricing still sits above what compounded programs charge, and coverage for weight management drugs remains uneven, with Medicare Part D historically excluding drugs used for weight loss. For many cash payers the practical choice is a compounded program or nothing, which is precisely why the comparison needs to be done on total cost rather than on principle.
Where comparison pages help and where they mislead
Side by side write-ups are useful for the checklist they generate. They are less useful as verdicts, because a large share of them are published by competing providers. A Medvi comparison hosted at formblends.com is one example of that pattern, and reading it alongside the provider’s own terms rather than instead of them is the sensible approach.
The neutral test is whether a page shows its arithmetic. A comparison that lists maintenance dose pricing, fees, and exit terms in the same table is doing real work. One that ranks providers with no numbers attached is an advertisement with a table in it.
What the clinical evidence does and does not settle
Efficacy differences between the two main molecules are reasonably well described. A retrospective comparison of semaglutide and tirzepatide in adults with overweight or obesity found greater weight reduction with tirzepatide. Separately, the tirzepatide obesity registration trial and the semaglutide registration trial each reported substantial mean reductions against placebo, though those were separate trials in different populations and cannot be read as a head to head result.
What the evidence does not settle is which provider to use. No trial compares telehealth platforms. Clinical guidelines describe pharmacotherapy as long term treatment paired with lifestyle support, which shifts the value question toward whether a program is affordable and workable for a year rather than which one has the better landing page.
Frequently asked questions
Is the cheapest program usually the best value?
Rarely, once maintenance dose pricing and fees are added. A program with a higher headline price that includes shipping, dose increases and clinician messaging can total less over a year than one that prices each element separately. Run the twelve month number on the dose actually expected to be reached.
Do the manufacturer direct channels count as alternatives?
Yes, and they should be priced alongside the telehealth options. They supply FDA-approved medication rather than compounded preparations, which is a material difference. They generally cost more per month, so the comparison is between a known approved product and a lower price for a preparation no agency has reviewed.
Does insurance change the comparison?
Substantially, where it applies. Coverage for weight management medication varies widely by plan and many exclude it, and Medicare Part D has historically excluded drugs used for weight loss. Anyone with commercial coverage should price the approved route through their own plan before assuming cash pay is cheaper.
How much does provider choice affect results?
Less than dose adherence and duration do. Guidelines treat obesity pharmacotherapy as ongoing rather than a fixed course, and the trials show weight returning after withdrawal. A program the patient can afford and stay with for a year is likely to outperform a cheaper one they leave in month three.
What single question separates the field fastest?
Ask what the highest dose costs per month, including every fee, and what happens to money already paid if the plan ends early. Providers with clean answers to both tend to have clean terms elsewhere. Vague answers to either are the strongest available signal at the point of comparison.
